SRAX Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de SRAX.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Software	16.9%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como SRAX no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OTCPK:SRAX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2022	28	-32	-13	-12	N/A
9/30/2022	28	-22	-14	-13	N/A
6/30/2022	30	-21	-19	-18	N/A
3/31/2022	29	-3	-24	-23	N/A
12/31/2021	27	-10	-24	-23	N/A
9/30/2021	21	-6	-23	-22	N/A
6/30/2021	17	-4	-22	-21	N/A
3/31/2021	11	-11	-17	-17	N/A
12/31/2020	6	-10	-14	-13	N/A
9/30/2020	5	-19	-14	-13	N/A
6/30/2020	4	-11	-13	-12	N/A
3/31/2020	3	-14	-16	-15	N/A
12/31/2019	4	-17	-17	-15	N/A
9/30/2019	4	-21	-19	-17	N/A
6/30/2019	5	-1	-23	-22	N/A
3/31/2019	8	3	-17	-16	N/A
12/31/2018	10	9	-15	-14	N/A
9/30/2018	15	10	-12	-11	N/A
6/30/2018	19	-14	-4	-3	N/A
3/31/2018	20	-11	-5	-4	N/A
12/31/2017	23	-13	-5	-4	N/A
9/30/2017	28	-8	-5	-4	N/A
6/30/2017	32	-7	-4	-4	N/A
3/31/2017	36	-4	-2	-2	N/A
12/31/2016	36	-4	-1	-1	N/A
9/30/2016	32	-3	N/A	3	N/A
6/30/2016	30	-2	N/A	0	N/A
3/31/2016	32	-3	N/A	1	N/A
12/31/2015	30	-3	N/A	1	N/A
9/30/2015	26	-4	N/A	-1	N/A
6/30/2015	19	-4	N/A	-1	N/A
3/31/2015	9	-6	N/A	-3	N/A
12/31/2014	5	-4	N/A	-2	N/A
9/30/2014	3	-3	N/A	-2	N/A
6/30/2014	4	-3	N/A	-2	N/A
3/31/2014	4	-2	N/A	-1	N/A
12/31/2013	3	-2	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SRAX es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SRAX crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SRAX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SRAX crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de SRAX crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SRAX se prevé que sea elevada dentro de 3 años.

SRAX Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2023

Price target increased to US$10.50

Price target increased to US$10.50

SRAX, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

SRAX, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Consensus forecasts updated

Recent updates

DNA Holdings LLC entered into a definitive merger agreement to acquire remaining 65% stake in SRAX, Inc. (OTCPK:SRAX).

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. Announces Resignation of Board Members

Alan Urban Resigns as the Chief Financial Officer of SRAX, Inc

New major risk - Market cap size

First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.57 loss in 1Q 2021)

Forecast breakeven date pushed back to 2023

SRAX, Inc., Annual General Meeting, Dec 31, 2022

Price target increased to US$10.50

SRAX, Inc. Launches the Sequire Investor Community Platform

SRAX Announces Receipt of Nasdaq Listing Determination

SRAX gets Nasdaq delisting notice, plans to appeal decision

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.69 loss in FY 2020)

SRAX, Inc. Announces the Arcimoto Sweepstakes

SRAX Announces Receipt of Anticipated Nasdaq Notice of Additional Delinquency

Srax receives Nasdaq notice of additional delinquency

Is There An Opportunity With SRAX, Inc.'s (NASDAQ:SRAX) 50% Undervaluation?

Price target increased to US$10.50

SRAX announces $9.5M revolving credit facility

SRAX, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Receives Non-Compliance Notice from Nasdaq

SRAX, Inc. announced delayed annual 10-K filing

SRAX, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Is SRAX (NASDAQ:SRAX) A Risky Investment?

SRAX Offers Value Here

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.38 loss in 2Q 2020)

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

SRAX Is Booming, Except The Share Price

Consensus forecasts updated

SRAX, Inc. (NasdaqCM:SRAX) announces an Equity Buyback for $10 million worth of its shares.

Price target increased to US$9.75

SRAX Releases the 1x1 Meeting Feature on the Sequire Virtual Events Platform

SRAX Has Plenty Of Room To Run

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal 2021

Full year 2020 earnings released: US$0.92 loss per share (vs US$1.36 loss in FY 2019)

SRAX, Inc. Provides Revenue Guidance for the Second Quarter Of Fiscal Year 2021

SRAX, Inc. Releases the Shelf Registration Feature on the Sequire Platform

Brock Pierce Joins SRAX Board of Directors

SRAX trades high on Sequire platform reporting 3M retail investors

New 90-day high: US$3.95

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

New 90-day high: US$3.12

Analysts update estimates

SRAX, Inc., Annual General Meeting, Dec 31, 2020

Third quarter 2020 earnings released: US$0.45 loss per share

SRAX EPS misses by $0.14, beats on revenue

An undisclosed buyer acquired the remaining stake in the MD Asset of SRAX, Inc. (NasdaqCM:SRAX) for $8 million.

New 90-day low: US$2.34

SRAX, Inc. Announces Resignation of Kristoffer Nelson as Chief Operating Officer and as a Member of the Board, Effective October 16, 2020

SRAX, Inc. announced that it has received $14 million in funding from Serra Ventures, LLC

SRAX, Inc. (NasdaqCM:SRAX) completed the acquisition of LD Micro, Inc.

Analysts increase revenue estimates to US$5.72m

Analysts update estimates

New 90-day high - US$2.80

SRAX, Inc. announced that it has received $13 million in funding

SRAX, Inc.(NasdaqCM:SRAX) dropped from Russell Microcap Growth Index

SRAX, Inc. announced that it has received $11.8 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento